Enhancing Benefit With Durvalumab in NSCLC After the PACIFIC Trial

03 Dec 2019 01:45 0
Targeted Oncology Download
1 0

Andreas Rimner, MD, radiation oncologist, Memorial Sloan Kettering Cancer Center, gives an overview of his presentation on “Crossing the PACIFIC,” which he presented at the 2019 New York Lung Cancers Symposium.

Following the PACIFIC trial of durvalumab following concurrent chemoradiation in patients with stage III unresectable non–small cell lung cancer, the standard of care for this patient population was changed due to the magnitude of the benefit observed in the study.

There is now a question of how to move forward in prolonging progression-free survival and overall survival after the PACIFIC trial.

Considering several ideas which were to give durvalumab even earlier, combing durvalumab with other drugs enhance the effects, and can it be given to patients who are not fit for the classic PACIFIC regimen and can it be given to surgical candidates.

The data that exist in regard to these ideas are not extensive, but immunotherapy has shown some promise, says Rimner.

Visit www.TargetedOnc.com for more videos related to lung cancer and other malignancies.

Related of "Enhancing Benefit With Durvalumab in NSCLC After the PACIFIC Trial" Videos